- Stérilité
- Published:
Les traitements médicaux de l’oligoasthénozoospermie idiopathique
Revue de la littérature
Medical treatment of idiopathic oligoasthenozoospermia
Literature review
Andrologie volume 8, pages 47–56 (1998)
Resume
Dans un nombre élevé de cas, l’infertilité d’un couple résulte d’une oligoasthénozoospermie dont aucune étiologie ne peut être reconnue. Différentes thérapeutiques médicales ont été proposées dans la littérature pour accroître la numération et la mobilité des spermatozoïdes. Nombre d’études observent une amélioration des paramètres spermiologiques sans prendre en compte les variations physiologiques et sans les comparer à des patients traités par un placebo. Pour d’autres, le but final du traitement n’est pas précisé c’est-à-dire l’obtention d’un enfant par le couple.
Dans cette revue de la littérature, seules les études randomisées précisant les taux de grossesses ont été prises en compte. Différentes hormones de l’axe hypothalamo-hypophyso-testiculaire ont été utilisées, le GnRH et ses analogues, les gonadotrophines et leurs formes purifiées, les anti-estrogènes, les androgènes et les inhibiteurs de l’aromatisation. Parmi ces molécules, des effets positifs ont été sporadiquement observés. Ainsi, la mestérolone stimulerait la spermatogenèse dans une étude sur cinq. L’undécanoate de testostérone et la FSH auraient des effets bénéfiques sur le pouvoir fécondantin vitro. Deux anti-estrogènes ont été testés, le clomifène et le tamoxifène avec des taux de grossesse significativement augmentés mais cependant des effets paradoxaux ont été observés. D’autres molécules, non hormonales, ont également fait l’objet de travaux. La plus étudiée est la kallicréine, une glycoprotéine impliquée dans la libération des kinines à partir du kininogène. Des résultats contradictoires ont été obtenus avec cette thérapie. La pentoxifylline, un inhibiteur de la phosphodiestérase est activein vitro mais n’a pas encore fait ses preuvesin vivo. D’autres substances comme l’arginine, la carnitine, les α bloqueurs, les bloqueurs des mastocytes, l’acide folinique, les vitamines, etc, font l’objet de publications sporadiques et aucune conclusion ne peut être tirée.
En conclusion, l’oligoasthénozoospermie idiopathique semble toujours rebelle à la plupart des traitements dont nous disposons à ce jour. Dans ce cas, le choix d’une thérapie est empirique et devrait en cas d’échec être rapidement abandonné afin d’orienter le couple vers la procréation médicalement assistée.
Abstract
In number cases, couple infertility results of an oligoasthenozoospermia without any recognized etiology. Various medical therapies have been proposed in the literature to increase sperm count and their mobility. Some studies demonstrate an improvement of spermatic parameters without taking physiological variations into consideration and without comparing the results with those obtained in patients treated with a placebo. For others, the final aim of the treatment is not specified, that means to get a pregnancy by the couples.
In this review of literature, only randomized studies giving the pregnancy rate, were taken into account. Various hormones of the hypothalamo-hypophyso-testicular axe have been used. GnRH and its analogs, gonadothropins and their purified forms, antiestrogens, androgens and aromataze inhibitors. Among these molecules, positive effects have been sporadically observed. Mesterolone stimulated spermatogenesis in one on five studies. Testosterone undecanoate and FSH have a benefic effect onin vitro fertilization. Two antiestrogens have been tested for a couple of years. Clomiphene and tamoxifen induce a sifnificant increase in the pregnancy rates with however, some paradoxical effects. Other non hormonal molecules have also been studied. The oldest studied medication is kallicrein, a glycoprotein implicated in the release of kinins from kininogens. Contradictory results have been obtained with this therapy. Pentoxifyllin, a phosphodiesterase inhibitor is active on spermatozoa mobilityin vitro, but its activityin vivo is not demostrated.
Other medicators as arginin, carnitin, mast cell blockers, α-blockers, vitamins etc have also been tested. Publications are sporadic and any conclusion can be drawn.
In conclusion, idiopathic oligoasthenozoospermia seems still unamenable to treat. Choice of a therapy is empirical and must be leaved for trying a medically assisted treatment
References
AAFJES J., VAN DER VIJVER J., BRUGMAN F. & SCHENK P. Double-blind cross over treatment with mesterolone and placebo of subfertile oligozoospermic men-value of testicules biopsy. Andrologia, 1983, 15: 531–535.
ACOSTA A.A. Pharmacologic improvement of the sperm function: treatment of the patient. In J. Tesarick ed. Male Factor in human infertility. Frontiers in Endocrinology vol 8. Ares sereno symposia, 1994: 217–255.
ACOSTA A.A., KHALIFA E. & OEHNINGER S. Pure human follicle-stimulating hormone has a role in the treatment of severe male infertility by assisted reproduction: Norfolk’s total experience. Human Reprod., 1992, 7: 1067–1072.
AINMELK Y., BELISLE S., CARMEL M. & TETREAULT L. Tamoxifen citrate therapy in male infertility. Fertil. Steril., 1987, 48: 113–117.
AINMELK Y., BELISLES S., KANDALAFT N., McCLURE D., TETREAULT L. & ELMILALI M. Bromocriptine therapy in oligozoospermic infertile men. Arch. Androl., 1982, 8: 135–141.
AYDAN S., INCI O. & ALAGOL B. The role of argenin, indomethacin and kallikrein in the treatment of oligoasthenospermia. Int. Urol. and Nephrol., 1995, 27: 199–202.
BAKER H.W.G., BURGER H.G., de KRETSER D.M. & HUDSON B. Relative incidence of etiological disorders in male infertility. In: Santen R.J. & Swerdloff R.S. eds. Male Reproductive Dysfunction. New York, Marcel Dekker, USA, 1986, 341–372.
BARTOOV B., ELTES F., LUNENFELD E., HAREVEN D., LEDERMAN H. & LUNENFELD B. Sperm quality of subfertile male before and after treatment with human follicle-stimulating hormone. Fertil. Steril., 1994, 61: 727–734.
BEDFORD N. & ELSTEIN M. The effect of kallikrein in male infertility: a double blind study. In: Insler V. & Bettendorf G. eds. Diagnosis and Treatment of infertility. Elsevier, Amsterdam, 1981: 339–344.
BENNET A. Place des traitements par FSH dans les stérilités masculines. Contracept. Fertil. Sex., 1992, 20: 705–707.
BENTIVOGLIO G., MELICA F. & CRISTOFORONI P. Folinic acid in the treatment of human male infertility. Fertil. Steril., 1993, 60: 698–701.
BREZNIK R. & BORKO E. Effectiveness of antiestrogens in infertile men. Archives of Andrology, 1993, 31: 43–48.
CHECK J., CHASE J., NOWROOZI K., WU C. & ADELSON M. Empirical therapy of the male with clomiphen in couple with unexplained infertility. Int. J. Fertil., 1989, 34: 120–122.
CLARK R. & SHERINS R. Clinical trial of testolactone for treatment of idiopathic male infertility. J. Androl., 1989, 10: 240–247.
COMHAIRE F.H. Tamoxifen. In: Bain J., Schill W.P. & Schwarzstein L. eds. Treatment of male infertility. Springer Verlag, Berlin, 1982: 45–53.
COMHAIRE F.H. Treatment of idiopathic testicular failure with high dose testosterone undecanoate a double blind pilot study. Fertil. Steril., 1990, 54: 689–693.
COMHAIRE F.H., SCHOONJANS F., ABDELMASSIH R. et al. Does treatment with testisterone undecanoate improve the in vitro fertilizing capacity of spermatozoa in patients with idiopathic testicular failure? (results of a double blind study). Hum. Reprod., 1995, 10: 2600–2602.
COSTA M., CANALE D., FILICORI M., D’IDDIO S. & LENZI A. L-Carnitine in idiopathic asthenozoospermia: a multicenter study. Andrology, 1994, 26: 155–159.
CROTTAZ B., SENN A., REYMOND M.J., REY F., GERMOND M., GOMEZ F. Follicle stimulating hormone bioactivity in idiopathic normagonadotropic olidoasthenozoospermia: double blind trial with gonadotropin-releasing hormone. Fertil. Steril., 1992, 57: 1034–1043.
GERRIS J., COMHAIRE F., HELLEMANS P., PEETERS K., SCHOONJANS F. Placebo-controlled trial of high-dose mesterolone treatment of idiopathic male infertility. Fertil. Steril., 1991, 55: 603–607.
GILBAUGH J.H. & LIPSHULTZ L.I. Non surgical treatment of male infertility. Urologic Clinics of North America, 1994: 21, 531–548.
GLASS A.R. Paradoxical suppression of spermatogenesis during tamoxifen treatment of oligospermia. Fertil. Steril., 1988, 49: 376–377.
GLEZERMAN M., LUNENFELD E., POTASHNIK G., HULEINEL M., SOFFER Y. & SEGAL S. efficacy of kallicrein in the treatment of oligozoospermia and asthenozoospermia: a double blind trial. Fertil. Steril., 1993, 60: 1052–4056.
GREGORIOU O., PAPADIAS C., GARGAROPOULOS A., KONIDARIS S., KONTOGEORGI Z. & KALAMPOKAS E. Treatment of idiopathic infertility with testosterone undecanoate a double blind study. Clin. Exp. Obst. Gyn., 1993, XX: 9–12.
HARGREAVE T.B., SWEETING V.M. & ELTON R.A. Randomized trial tamoxifen versus vitamin C for male infertility. Proceedings of the 12th World Congress on Fertility and Sterility (Singapour), 1986, 9: 51–57.
HOVATTA O., KOSKIMIES A., RANTA T., STENMAN U.H. & SEPPALA M. Bromocriptine treatment of oligospermia a double blind study. Clin. Endocrinol., 1979, 11: 377–382.
IACONO F., BARRA S., MONTANO L. & LOTTI T. Interêt de la FSH à forte dose dans le traitement de l’infertilité masculine idiopathique. J. Urol., 1996, 102: 81–84.
IZZO P., CANALE D., BIANCHI B. et al. H. The treatment of male sulfertility with kallicrein. Andrologia, 1984, 16: 156–161.
KECK C., BEHRE H. M., JOCKENHOVEL F. & NIESCHLAG E. Ineffectiveness of kallicrein in treatment of male infertility: a double-blind, randomized, placebo-controlled trial. Human Reprod., 1994, 9: 325–329.
KNUTH U.A., HONIGL W., BALS-PRATSCH M., SCHLEICHER G. & NIESCHLAG E. Treatment of severe oligospermia with human chorionic gonadotropin/human menopausal gonadotropin: a placebocontrolled, double blind trial. J. Clin. Endocrinol. Metab., 1987, 65: 1081–1087.
KRAUSE W., HOLLAND-MORITZ H. & SCHRAMM P. Treatment of idiopathic oligozoospermia with tamoxifen — a randomized controlled study. Int. J. Androl., 1992, 15: 14–18.
LEE K.O., NG S.C., LEE P.S. et al. Effect of growth hormone therapy in men with severe idiopathic oligospermia. Eur. J. Endocrinol., 1995, 132: 159–162.
LUNGLMAYR G., MAIER U. & SPONA J. Therapie der idiopathieschen Oligozoospermie mit Bromokriptin Resultate einer prospektive kontrollierten Studie. Andrologia, 1983, 15: 548–553.
MICIC S., BILA S., ILIC V. & SULOVIC V. Treatment of men with oligoasthenozoospermia and asthenozoospermia with kallikrein. Acta Eur. Fertil., 1985, 16: 51–53.
MICIC S. & DOTLIC R. Evaluation of sperm parameters in clinical trial with clomiphene citrate of oligospermic men. J. Urol., 1985, 133: 211–222.
O’DONOVAN P.A., VANDEKERCKHOVE P., LILFORD R.J. & HUGHES E. Treatment of male infertility: is it effective? Review and meta-analysis of published randomized controlled trials. Hum. Reprod., 1993, 8: 1209–1222.
OVESEN P., JORGENSEN J.O.L., INGERSLEV J., HO K.K.Y., ORSROV H. & CHRISTIANSEN J.S. Growth hormone treatment of subfertile males. Fertil. Steril., 1996, 66: 292–298.
PAULSON D. Cortisone acetate versus clomiphene citrate in pregerminal idiopathic oligospermia. J. Urol., 1979, 121: 432–434.
PRYOR J., BLANDY J., EVENS P., CHAPUT de SAINTONGE D. & USHERWOOD M. Controlled clinical trial of arginine for infertile men with oligozoospermia. Br. J. Urol., 1978, 50: 47–50.
PUSCH H.H. Oral treatment of oligozoospermia with testosterone-undecanoate: results of a double-blind placebo controlled trial. Andrologia, 1989, 21: 76–82.
RADICIONI A., PARIS E., DONDERO F., BONIFACIO V. & ISIDORI Q. Recombinant-growth hormone (rec-LGH) therapy in infertile men with idiopathic oligozoospermia. Acta Eur. Fertil., 1994, 25: 311–317.
ROGERS B.O., THOMPSON T.G., GIBSON C.K., HERBERT C.M., MAX W.S. & FARR C. The effectiveness of tamoxifen and serophene in treatment of male infertility. Am. Fertil. Soc., 1988, abstract: 609 847.
RONNBERG L. The effect of clomiphene citrate in different sperm parameters and serum hormone levels in preselected infertile men: a controlled double blind study. Int. J. Androl., 1980, 3: 479–486.
SCHELLEN A.M.C.M. Clomiphene citrate in the treatment of male infertility. In: Bain J., Schill W.B. & Schwarzstein L. eds. Treatment of male infertility. Springer Verlag Berlin, 1982: 33–44.
SCHILL W.B. Treatment of idiopathic oligozoospermia by kallikrein: results of double blind study. Archiv. Androl., 1979, 2: 163–170.
SCHILL W.B. Kinin-releasing pancreaticproteinase kallicrein. Treatment of male infertility. In: Bain J., Schill W.B. & Schwarzstein L. eds. Springer Verlag Berlin, 1982: 125–142.
SCHILL W.B., SCHNEIDER J. & RING J. The use of ketotifen, a mast cell blocker, for treatment of oligoand asthenozoospermia. Andrologia, 1986, 18: 570–573.
SCHWARZSTEIN L. & APARICIO N. LHRH and its analogs in the treatment of idiopathic normagonadotropic oligozoospermia. In: Bain J., Schill W., Schwarzstein L. eds. Treatment of male infertility. Springer-Verlag, Berlin, 1982: 55–69.
Scottish Infertility Group: ABEL B., CARSWELL G., ELTON R. et al. Randomised trial of clomiphene citrate treatment and vitamin C for male infertility. Br. J. Urol., 1982, 54: 780–784.
Scottish Infertility Group: HARGRAEVE T., KYLE K., BAYBY K. et al. Randomised trial of mesterolone versus vitamin C for male infertility. Br. J. Urol., 1984, 56: 740–744.
SITERMAN S., ELTES F., WOLFSON V., ZABLU-DOWSKY N. & BARTOOV B. Effect of acupuncture on sperm parameters of males suffering from subfertility related to low sperm quality. Archives of Andrology, 1997, 39: 155–161.
SOKOL R., STEINER B., BUSTILLO M., PETERSEN G. & SWERDLOFF R. A controlled comparison of the efficacy of clomiphene citrate in male infertility. Fertil Steril. 1988, 49: 865–870.
SULEIMAN S.A., ALI M.E., ZAKI Z.M.S., ELMALIK E.M.A. & NASR M.A. Lipid peroxidation and human sperm mobility. Protective role of vitamin E. J. Androl., 1996, 17: 530–537.
TOROK L. Treatment of oligozoospermia with tamoxifen (open and controlled studies). Andrologia, 1985, 17: 497–501.
TOURNAYE H., VAN STEIRTEGHEM A.C. & DEVROEY P. Pentoxifylline in idiopathic male-factor infertility: a review of its therapeutic efficacy after oral administration. Hum. Reprod., 1994, 9: 996–1000.
VANDERKERCKHOVE P., O’DONOVAN P.A., LILFORD R.J. & HARADA T.W. Infertility treatment: from cookery to science. The epidemiology of randomised controlled trials. Br. J. Obstet. Gynaecol., 1993, 100: 1005–1036.
VARMA T.R. & PATEL H.R. The effect of mesterolone on sperm count, on serum follicle stimulating hormone, luteinizing hormone, plasma testosterone and outcome in idiopathic oligospermic men. Int. J. Gynecol. Obstet., 1988, 26: 121–128.
VITALI G., PARENTE R. & MELOTTI C. Carnitine supplementation in human idiopathic asthenospermia: clinical results. Drug Exp. Clin. Res., 1995, 21: 157–159.
WANG G., CHAN C.W., WONG K.K. & YEUNG K.K. Comparison of the effectiveness of placebo clomiphene citrate mesterolone pentoxifylline and testosterone rebound therapy for the treatment of idiopathic oligospermia. Fertil. Steril., 1983, 40: 358–364.
WHO. Task force on the diagnosis and treatment of infertility. Mesterolone and idiopathic male infertility a double blind study. Int. J. Androl., 1989, 12: 254–264.
WHO. A double blind trial of clomiphene citrate for the treatment of idiopathic male infertility. Int. J. Androl., 1992, 15: 299–307.
WIELAND R., ANSARI A., KLEIN D., DOSHI N., HALLBERG M. & CHEN J. Idiopathic oligospermia: control observations and response to cisclomiphene. Fertil. Steril., 1972, 23: 471–474.
YAMAMOTO M., HIBI H. & MIYAKE K. Comparison of the effectiveness of placebo and α-blocker therapy for the treatment of idiopathic oligozoospermia. Fertil. Steril., 1995, 63: 396–400.
YAMAMOTO M., HIBI H. & MIYAKE K. New treatment of idiopathic severe oligozoospermia with mast cell blocker: results of a single blind study. Fertil. Steril., 1995, 64: 1221–1223.
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Demoulin, A. Les traitements médicaux de l’oligoasthénozoospermie idiopathique. Androl. 8, 47–56 (1998). https://doi.org/10.1007/BF03034761
Issue Date:
DOI: https://doi.org/10.1007/BF03034761